The Influence of −174 G/C Interleukin 6 Promoter Gene Polymorphism to Interleukin 6 Concentration in the End Stage Renal Disease Patients with Dialysis: A Single-center Experience in Indonesia
DOI:
https://doi.org/10.3889/oamjms.2020.4715Keywords:
Interleukin-6, Gene, ESRDAbstract
BACKGROUND: Chronic kidney disease (CKD) is classified as a multifactorial disease as a combination of genetic and environmental factors that affect the onset and progression of end-stage renal disease (ESRD). In the last decades are recognized that inflammation, where the critical modulator is cytokines, can occur before the onset of kidney disease and can be a causative factor in the development of CKD. Interleukin (IL)-6 has several polymorphisms in the promoter region, such as 174 G-C, 634 C-G, 572 G-C, and 597 G-A. G/C single nucleotide polymorphism of the IL-6 gene at position 174 in the promoter region is reported to affect the level of IL-6 expression. Unfortunately, there is a lack of data about the genotype frequencies of -174 G/C IL-6 promoter gene polymorphism in Indonesian with ESRD.
AIM: This study aimed to analyze whether −174 G/C IL-6 promoter gene polymorphism influences the concentration of IL-6 in ESRD patients with dialysis in Indonesia.
METHODS: We recruited 95 outpatients who were undergoing regular hemodialysis for ≥3 months at the Rasyida Renal Hospital, Medan, in this cross-sectional study. IL-6 genotype polymorphism was analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The enzyme-linked immunosorbent assay method was performed to assess the quantitative IL-6 serum.
RESULTS: PCR-RFLP examination showed the frequency distribution of the IL-6 genotype -174 G/C gene; 72 (75.8%) respondents had GG genotypes; 22.1% of respondents had the CG genotype, and (2.1%) had the CC genotypes. Patients with the CC genotype were statistically significant to have higher IL-6 concentration compared to other genotypes (p < 0.001). Likewise, with diabetic patients, statistics showed higher IL-6 concentration compared to non-diabetics patients (p < 0.001).
CONCLUSION: This is the first study showing that -174 G/C IL-6 promoter gene polymorphism influences the IL-6 concentrations in ESRD patients with dialysis in Indonesia. Multicenter studies are needed to validate these findings.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Prodjosudjadi W, Suhardjono A. End-stage renal disease in Indonesia: Treatment development. Ethn Dis. 2009;19(1):33. PMid:19484872
Yang H, Lu K, Lee H, Huang S, Lin Y, Wu C, et al. Role of the functional toll-like receptor-9 promoter polymorphism (-1237T/C) in increased risk of end-stage renal disease: A case-control study. PLoS One. 2013;8(3):e58444. https://doi.org/10.1371/ journal.pone.0058444 PMid: 23472199
Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007;72(5):549-56. https:// doi.org/10.1038/sj.ki.5002391 PMid:17579660
Shanmuganathan R, Ramanathan K, Padmanabhan G, Vijayaraghavan B. Evaluation of interleukin 8 gene polymorphism for predicting inflammation in Indian chronic kidney disease and peritoneal dialysis patients. Alex J Med. 2017;53(3):215-20. https://doi.org/10.1016/j.ajme.2016.06.004
Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res. 2007;150(2):101-5. https://doi.org/10.1016/j.trsl.2007.03.003
Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2008;19(3):329-45. PMid:18445891
Aker S, Bantis C, Reis P, Kuhr N, Schwandt C, Grabensee B, et al. Influence of interleukin-6G-174C gene polymorphism on coronary artery disease, cardiovascular complications, and mortality in dialysis patients. Nephrol Dial Transplant. 2009;24(9):2847-51. https://doi.org/10.1093/ndt/gfp141
Ng DP, Nurbaya S, Ye SH, Krolewski AS. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in Type 2 diabetic patients. Kidney Int. 2008;74(4):521- 7. https://doi.org/10.1038/ki.2008.202 PMid:18496509
Ranganath P, Tripathi G, Sharma RK, Sankhwar SN, Agrawal S. Role of non-HLA genetic variants in end-stage renal disease. Tissue Antigens. 2009;74(2):147-55. https://doi. org/10.1111/j.1399-0039.2009.01276.x PMid:19497039
Buckham TA, McKnight AJ, Benevente D, Courtney AE, Patterson CC, Simmonds M. Evaluation of five interleukin genes for association with end-stage renal disease in white Europeans. Am J Nephrol. 2010;32(2):103-8. https://doi. org/10.1159/000314943 PMid:20551628
Kandil MH, Magour GM, Khalil GI, Maharem DA, Nomair AM. Possible association of interleukin-1beta (-511C/T) and interleukin-6 (-174G/C) gene polymorphisms with atherosclerosis in end-stage renal disease Egyptian patients on maintenance hemodialysis. Egypt J Med Hum Genet. 2013;14(3):267-75. https://doi.org/10.1016/j.ejmhg.2013.04.001
Jančić I, Arsenović-Ranin N, Šefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, et al. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int. 2012;33(6):1481-6. https://doi.org/10.1007/s00296-012-2586-y PMid:23233117
Su H, Lei C, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: An update. Front Immunol. 2017;8:405. https://doi.org/10.3389/fimmu.2017.00405 PMid:28484449
Beberashvili I, Sinuani I, Azar I, Yasur H, Shapiro G, Feldman L, et al. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(9):2253- 63. https://doi.org/10.2215/cjn.01770211 PMid:21852667
Downloads
Published
How to Cite
License
Copyright (c) 2020 Riri Andri Muzasti, Herman Hariman, Elvita Rahmi Daulay (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
